BR112016013714A8 - compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica - Google Patents
compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica Download PDFInfo
- Publication number
- BR112016013714A8 BR112016013714A8 BR112016013714A BR112016013714A BR112016013714A8 BR 112016013714 A8 BR112016013714 A8 BR 112016013714A8 BR 112016013714 A BR112016013714 A BR 112016013714A BR 112016013714 A BR112016013714 A BR 112016013714A BR 112016013714 A8 BR112016013714 A8 BR 112016013714A8
- Authority
- BR
- Brazil
- Prior art keywords
- sofosbuvir
- antiviral
- analogs
- pharmaceutical composition
- crystalline compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical class N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 2
- -1 (phenoxy) phosphorylamino Chemical group 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
as formas sólidas cristalinas do composto anti-hcv 2-((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-di-hidropirimidin-1(2h)-il)-4-fluoro-3-hidróxi-4-metiltetraidrofuran-2-il)metóxi)(fenóxi)fosforilamino)propanoato de (s)-isopropila (composto i) são descritas. são também fornecidos, os processos de preparação e os métodos de uso das formas cristalinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361920371P | 2013-12-23 | 2013-12-23 | |
PCT/US2014/069123 WO2015099989A1 (en) | 2013-12-23 | 2014-12-08 | Crystalline forms of antiviral sofosbuvir analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016013714A2 BR112016013714A2 (pt) | 2017-08-08 |
BR112016013714A8 true BR112016013714A8 (pt) | 2020-05-26 |
Family
ID=52146765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016013714A BR112016013714A8 (pt) | 2013-12-23 | 2014-12-08 | compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica |
Country Status (27)
Country | Link |
---|---|
US (1) | US9340568B2 (pt) |
EP (1) | EP3086795A1 (pt) |
JP (1) | JP2017503015A (pt) |
KR (1) | KR20160099710A (pt) |
CN (1) | CN105873593A (pt) |
AP (1) | AP2016009254A0 (pt) |
AR (1) | AR098929A1 (pt) |
AU (1) | AU2014370299B2 (pt) |
BR (1) | BR112016013714A8 (pt) |
CA (1) | CA2934799A1 (pt) |
CL (1) | CL2016001509A1 (pt) |
CR (1) | CR20160288A (pt) |
CU (1) | CU20160096A7 (pt) |
DO (1) | DOP2016000141A (pt) |
EA (1) | EA201691029A1 (pt) |
HK (1) | HK1222334A1 (pt) |
IL (1) | IL246066A0 (pt) |
MD (1) | MD20160087A2 (pt) |
MX (2) | MX2016008453A (pt) |
MY (1) | MY178102A (pt) |
PE (1) | PE20160750A1 (pt) |
PH (2) | PH12019500372A1 (pt) |
SG (1) | SG11201604818SA (pt) |
TW (1) | TW201609785A (pt) |
UY (1) | UY35917A (pt) |
WO (1) | WO2015099989A1 (pt) |
ZA (1) | ZA201604345B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100503628C (zh) | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
EP3154526B1 (en) | 2014-06-13 | 2019-03-06 | ratiopharm GmbH | Solid state forms of sofosbuvir |
WO2016023906A1 (en) * | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
WO2016156512A1 (en) * | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
US20180228828A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20180228827A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20180228826A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
WO2017029408A1 (en) * | 2015-08-20 | 2017-02-23 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
EP3430023A1 (en) | 2016-03-17 | 2019-01-23 | Mylan Laboratories, Limited | Polymorphic forms of sofosbuvir |
CZ2016257A3 (cs) | 2016-05-05 | 2017-11-15 | Zentiva, K.S. | Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace |
BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
US20190185507A1 (en) | 2016-08-19 | 2019-06-20 | Sandoz Ag | Sofosbuvir Derivatives for the Treatment of Hepatitis C |
CN108084237A (zh) * | 2016-11-23 | 2018-05-29 | 广东东阳光药业有限公司 | 索非布韦的一水合物及其制备方法 |
EA201990780A1 (ru) * | 2016-12-22 | 2019-11-29 | Твердая форма соединения 4'-тио-2'-фторнуклеозид фосфамида и способ его получения и применения | |
RU2656228C9 (ru) * | 2017-06-13 | 2019-04-16 | Олег Ростиславович Михайлов | Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе |
EP3661944A1 (en) | 2017-08-03 | 2020-06-10 | Sandoz AG | Sofosbuvir hydrate |
AU2018378832B9 (en) | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦新晶型及其制备方法 |
RU2745293C1 (ru) * | 2019-12-26 | 2021-03-23 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения кристаллической формы 8 софосбувира (варианты) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2857394A1 (en) | 2009-05-13 | 2015-04-08 | Gilead Pharmasset LLC | Antiviral compounds |
TWI576352B (zh) * | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) * | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
HUE026235T2 (en) * | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
WO2011123654A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
-
2014
- 2014-12-04 TW TW103142194A patent/TW201609785A/zh unknown
- 2014-12-08 CN CN201480070460.XA patent/CN105873593A/zh active Pending
- 2014-12-08 US US14/563,639 patent/US9340568B2/en active Active
- 2014-12-08 MX MX2016008453A patent/MX2016008453A/es unknown
- 2014-12-08 EA EA201691029A patent/EA201691029A1/ru unknown
- 2014-12-08 WO PCT/US2014/069123 patent/WO2015099989A1/en active Application Filing
- 2014-12-08 PH PH12019500372A patent/PH12019500372A1/en unknown
- 2014-12-08 CA CA2934799A patent/CA2934799A1/en not_active Abandoned
- 2014-12-08 BR BR112016013714A patent/BR112016013714A8/pt not_active IP Right Cessation
- 2014-12-08 MD MDA20160087A patent/MD20160087A2/ro not_active Application Discontinuation
- 2014-12-08 SG SG11201604818SA patent/SG11201604818SA/en unknown
- 2014-12-08 AP AP2016009254A patent/AP2016009254A0/en unknown
- 2014-12-08 MY MYPI2016702283A patent/MY178102A/en unknown
- 2014-12-08 PE PE2016000813A patent/PE20160750A1/es unknown
- 2014-12-08 AU AU2014370299A patent/AU2014370299B2/en not_active Ceased
- 2014-12-08 JP JP2016560620A patent/JP2017503015A/ja active Pending
- 2014-12-08 EP EP14819226.3A patent/EP3086795A1/en not_active Withdrawn
- 2014-12-08 CR CR20160288A patent/CR20160288A/es unknown
- 2014-12-08 KR KR1020167019760A patent/KR20160099710A/ko not_active Application Discontinuation
- 2014-12-22 AR ARP140104873A patent/AR098929A1/es unknown
- 2014-12-23 UY UY0001035917A patent/UY35917A/es not_active Application Discontinuation
-
2016
- 2016-06-06 IL IL246066A patent/IL246066A0/en unknown
- 2016-06-15 DO DO2016000141A patent/DOP2016000141A/es unknown
- 2016-06-15 CL CL2016001509A patent/CL2016001509A1/es unknown
- 2016-06-20 PH PH12016501203A patent/PH12016501203B1/en unknown
- 2016-06-22 CU CUP2016000096A patent/CU20160096A7/es unknown
- 2016-06-23 MX MX2019005253A patent/MX2019005253A/es unknown
- 2016-06-27 ZA ZA2016/04345A patent/ZA201604345B/en unknown
- 2016-09-06 HK HK16110590.5A patent/HK1222334A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112016013714A2 (pt) | 2017-08-08 |
UY35917A (es) | 2015-05-29 |
AU2014370299B2 (en) | 2017-11-30 |
AU2014370299A1 (en) | 2016-06-23 |
ZA201604345B (en) | 2017-11-29 |
PE20160750A1 (es) | 2016-07-27 |
SG11201604818SA (en) | 2016-07-28 |
TW201609785A (zh) | 2016-03-16 |
CL2016001509A1 (es) | 2016-12-02 |
KR20160099710A (ko) | 2016-08-22 |
CA2934799A1 (en) | 2015-07-02 |
PH12016501203A1 (en) | 2016-08-15 |
JP2017503015A (ja) | 2017-01-26 |
AP2016009254A0 (en) | 2016-06-30 |
MY178102A (en) | 2020-10-02 |
CN105873593A (zh) | 2016-08-17 |
PH12019500372A1 (en) | 2020-03-02 |
EP3086795A1 (en) | 2016-11-02 |
EA201691029A1 (ru) | 2017-01-30 |
WO2015099989A1 (en) | 2015-07-02 |
PH12016501203B1 (en) | 2016-08-15 |
CR20160288A (es) | 2016-08-31 |
DOP2016000141A (es) | 2016-07-15 |
HK1222334A1 (zh) | 2017-06-30 |
US20150175646A1 (en) | 2015-06-25 |
US9340568B2 (en) | 2016-05-17 |
MD20160087A2 (ro) | 2016-12-31 |
CU20160096A7 (es) | 2016-11-29 |
MX2019005253A (es) | 2019-08-05 |
IL246066A0 (en) | 2016-07-31 |
AR098929A1 (es) | 2016-06-22 |
MX2016008453A (es) | 2016-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016013714A8 (pt) | compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica | |
CL2011000716A1 (es) | Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c. | |
CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
GEP201706793B (en) | Substituted nucleosides, nucleotides and analogs thereof | |
CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
CL2013003262A1 (es) | Compuestos derivados de 1,3-oxazinas, con actividad inhibidora de bace 1 y/o bace2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes, trombosis arterial, cáncer, infarto al miocardio, entre otras patologías. | |
CL2013002939A1 (es) | Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
CL2008002228A1 (es) | Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas. | |
MA40239B1 (fr) | (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido[1',2':4,5]pyrazino[2,1-b]oxazépin-8-olate de sodium | |
CL2013002871A1 (es) | Compuestos derivados de 1,3-oxazinas con actividad inhibidora de bace 1 y bace 2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes tipo 2, trombosis arterial, cáncer, infarto al miocardio,lupus eritematoso, entre otros. | |
CL2010000520A1 (es) | Forma cristalina del propanoato de (s) - isopropil 2 -(((s) - (((2r,3r,4r,5r) - 5- (2,4-dioxo-3,4-dihidropirimidim-1(2h) -il)-4-fluoro-3-hidroxi-4-metitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino); proceso de preparacion; composicion framaceutica; y su uso para el tratamiento de una infeccion causada por el virus de la hepatitis c. | |
MX2017011386A (es) | NUCLEÓTIDOS DE PURINA ß-D-2'-DEOXI-2'A-FLUORO-2'-ß-C-SUSTITUIDOS-2 - MODIFICADOS-N6- SUSTITUIDOS PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITIS C. | |
CL2013000685A1 (es) | Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico. | |
PH12015502588B1 (en) | 4`-fluoro-2`-methyl substituted nucleoside derivatives | |
EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
FR3041640B1 (fr) | NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT | |
EA201691554A1 (ru) | 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа | |
CY1120530T1 (el) | Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση | |
EA201591512A1 (ru) | Борсодержащие молекулы, способы и составы | |
PH12015502589A1 (en) | 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives | |
EA201892376A1 (ru) | Комбинированный состав трех противовирусных соединений | |
EA202091341A1 (ru) | Пиразолопиримидины, обладающие активностью в отношении респираторно-синцитиального вируса (rsv) | |
CL2008001615A1 (es) | Compuestos derivados de di(hetero)aril-ciclohexano; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cardiopatias, arritmias, isquemias, entre otras. | |
BR112015023591A2 (pt) | processo para a preparação de 4-amino-1-((ls,4r,5s)-2-fluoro-4,5-di-hidróxi-3-hidroximetil-ciclopent-2-enii)-1h-pirimidin-2-ona | |
BR112015030589A8 (pt) | formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |